Spruce Biosciences, Inc. SPRB 深 沪
等待开盘 03-26 09:30:00 美东时间
69.97
+5.610
+8.72%
华盛通- 最 高80.00
- 今 开71.50
- 成交量 9.94万股
- 最 低 65.34
- 昨 收 64.36
- 总市值 9600.18万
- 52周最高 240.00
- 市盈率 静 --
- 换手率 7.25%
- 52周最低 7.26
- 委 比 0.00%
- 总股本 137.20万
- 历史最高 240.00
- 量 比 3.09
- 振 幅 22.78%
- 历史最低 7.26
- 每 手 1
- 风险率 39.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $170
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $180 to $170.
03-10 20:43
Spruce Biosciences shares are trading higher. The company reported its Q4 financial results.
Spruce Biosciences shares are trading higher. The company reported its Q4 finan...
03-10 01:51
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q4 EPS $(36.25) Misses $(4.22) Estimate
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(36.25) per share which missed the analyst consensus estimate of $(4.22) by 757.99 percent. This is a 15.2 percent increase over
03-09 19:27
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
Spruce Biosciences Completes Type B Meetings With FDA Regarding Its Upcoming Biologics License Application Submission For Tralesinidase Alfa Enzyme Replacement Therapy, Application Submission Now Anticipated In Q4 For Sanfilippo Syndrome Type B
Spruce Biosciences announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming biologics license application (BLA) submission for
02-18 20:20
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and developme...
01-19 08:02
Spruce Biosciences Strikes Up To $50M, 42-Month Loan Facility With Avenue Venture Opportunities Fund II
Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today
01-08 21:19
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
